• +1-646-491-9876
    • +91-20-67278686

    Search

    Neutropenia - Pipeline Review, H1 2017

    Neutropenia - Pipeline Review, H1 2017

    • Report Code ID: RW0001767478
    • Category Pharmaceuticals
    • No. of Pages 85
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Neutropenia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

    Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 2, 1, 4, 3, 1, 8 and 3 respectively.

    Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Neutropenia - Overview
    Neutropenia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Neutropenia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Neutropenia - Companies Involved in Therapeutics Development
    Adello Biologics LLC
    Apotex Inc
    Arven Ilac
    BeyondSpring Pharmaceuticals Inc
    Cellerant Therapeutics Inc
    Cleveland BioLabs Inc
    Coherus BioSciences Inc
    Dr. Reddy's Laboratories Ltd
    Eurofarma Laboratorios SA
    Intas Pharmaceuticals Ltd
    Ligand Pharmaceuticals Inc
    Lupin Ltd
    Mycenax Biotech Inc
    Prolong Pharmaceuticals LLC
    Richter Gedeon Nyrt
    Sandoz International GmbH
    USV Pvt Ltd
    Neutropenia - Drug Profiles
    ACN-8337 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARVMIC-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CBLB-612 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LG-7455 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    plinabulin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romyelocel-L - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-7 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tamibarotene - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neutropenia - Dormant Projects
    Neutropenia - Product Development Milestones
    Featured News & Press Releases
    Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
    Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
    Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
    Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)
    Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
    Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
    May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
    Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
    Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
    Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
    Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
    Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
    Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Neutropenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Neutropenia - Pipeline by Adello Biologics LLC, H1 2017
    Neutropenia - Pipeline by Apotex Inc, H1 2017
    Neutropenia - Pipeline by Arven Ilac, H1 2017
    Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
    Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017
    Neutropenia - Pipeline by Cleveland BioLabs Inc, H1 2017
    Neutropenia - Pipeline by Coherus BioSciences Inc, H1 2017
    Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
    Neutropenia - Pipeline by Eurofarma Laboratorios SA, H1 2017
    Neutropenia - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
    Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
    Neutropenia - Pipeline by Lupin Ltd, H1 2017
    Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017
    Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
    Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017
    Neutropenia - Pipeline by Sandoz International GmbH, H1 2017
    Neutropenia - Pipeline by USV Pvt Ltd, H1 2017
    Neutropenia - Dormant Projects, H1 2017
    Neutropenia - Dormant Projects, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Neutropenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Adello Biologics LLC
    Apotex Inc
    Arven Ilac
    BeyondSpring Pharmaceuticals Inc
    Cellerant Therapeutics Inc
    Cleveland BioLabs Inc
    Coherus BioSciences Inc
    Dr. Reddy's Laboratories Ltd
    Eurofarma Laboratorios SA
    Intas Pharmaceuticals Ltd
    Ligand Pharmaceuticals Inc
    Lupin Ltd
    Mycenax Biotech Inc
    Prolong Pharmaceuticals LLC
    Richter Gedeon Nyrt
    Sandoz International GmbH
    USV Pvt Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//neutropenia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//neutropenia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//neutropenia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments